Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Playing Nice Over REMS: FDA Sees Accutane As Model For Shared Systems

Executive Summary

FDA will use the Accutane risk management agreement between Roche and generic drug companies as a guide for implementing the Risk Evaluation & Mitigation Strategy "shared use" provision of the FDA Amendments Act

You may also be interested in...



iPLEDGE Again On FDA Advisory Agenda, This Time As An Example

"REMS-related topics" is the theme of a joint FDA advisory committee meeting Dec. 1 focused on the landmark iPLEDGE program as an example of the effect such programs have on the health care system.

REMS: Added Expense For Pharma, Increased Opportunity For Vendors

The first anniversary of REMS is March 25: one year from the effective date of the FDA Amendments Act provisions granting FDA authority to require Risk Evaluation and Mitigation Strategies for drugs that raise safety issues.

REMS: Added Expense For Pharma, Increased Opportunity For Vendors

The first anniversary of REMS is March 25: one year from the effective date of the FDA Amendments Act provisions granting FDA authority to require Risk Evaluation and Mitigation Strategies for drugs that raise safety issues.

Topics

UsernamePublicRestriction

Register

PS050569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel